NICE gives Aubagio the nod

Share this article:

The UK's price watchdog NICE has approved Sanofi's oral MS medication Aubagio for adults with relapsing-remitting multiple sclerosis, which means the National Health Service will begin funding the drug within the next three months.

Wednesday's thumbs-up is a re-tread. NICE told Sanofi in September that Sanofi had to provide cost-effectiveness data that would indicate the drug deserves a space on the formulary compared to what's already on the market. The drug costs around $22,500 per patient per year in the UK.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.